Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2012

Open Access 01-12-2012 | Research article

Interleukin 6, lipopolysaccharide-binding protein and interleukin 10 in the prediction of risk and etiologic patterns in patients with community-acquired pneumonia: results from the German competence network CAPNETZ

Authors: Katrin Zobel, Peter Martus, Mathias W Pletz, Santiago Ewig, Michael Prediger, Tobias Welte, Frank Bühling, CAPNETZ study group

Published in: BMC Pulmonary Medicine | Issue 1/2012

Login to get access

Abstract

Background

The aim of our study was to investigate the predictive value of the biomarkers interleukin 6 (IL-6), interleukin 10 (IL-10) and lipopolysaccharide-binding protein (LBP) compared with clinical CRB and CRB-65 severity scores in patients with community-acquired pneumonia (CAP).

Methods

Samples and data were obtained from patients enrolled into the German CAPNETZ study group. Samples (blood, sputum and urine) were collected within 24 h of first presentation and inclusion in the CAPNETZ study, and CRB and CRB-65 scores were determined for all patients at the time of enrollment. The combined end point representative of a severe course of CAP was defined as mechanical ventilation, intensive care unit treatment and/or death within 30 days. Overall, a total of 1,000 patients were enrolled in the study. A severe course of CAP was observed in 105 (10.5%) patients.

Results

The highest IL-6, IL-10 and LBP concentrations were found in patients with CRB-65 scores of 3-4 or CRB scores of 2-3. IL-6 and LBP levels on enrollment in the study were significantly higher for patients with a severe course of CAP than for those who did not have severe CAP. In receiver operating characteristic analyses, the area under the curve values for of IL-6 (0.689), IL-10 (0.665) and LPB (0.624) in a severe course of CAP were lower than that of CRB-65 (0.764) and similar to that of CRB (0.69). The accuracy of both CRB and CRB-65 was increased significantly by including IL-6 measurements. In addition, higher cytokine concentrations were found in patients with typical bacterial infections compared with patients with atypical or viral infections and those with infection of unknown etiology. LBP showed the highest discriminatory power with respect to the etiology of infection.

Conclusions

IL-6, IL-10 and LBP concentrations were increased in patients with a CRB-65 score of 3-4 and a severe course of CAP. The concentrations of IL-6 and IL-10 reflected the severity of disease in patients with CAP. The predictive power of IL-6, IL-10 and LBP for a severe course of pneumonia was lower than that of CRB-65. Typical bacterial pathogens induced the highest LBP, IL-6 and IL-10 concentrations.
Appendix
Available only for authorised users
Literature
1.
go back to reference Welte T, Suttorp N, Marre R: CAPNETZ-community-acquired pneumonia competence network. Infection. 2004, 32: 234-238.CrossRefPubMed Welte T, Suttorp N, Marre R: CAPNETZ-community-acquired pneumonia competence network. Infection. 2004, 32: 234-238.CrossRefPubMed
2.
go back to reference Almirall J, Bolibar I, Vidal J, Sauca G, Coll P, Niklasson B, Bartolome M, Balanzo X: Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J. 2000, 15: 757-763. 10.1034/j.1399-3003.2000.15d21.x.CrossRefPubMed Almirall J, Bolibar I, Vidal J, Sauca G, Coll P, Niklasson B, Bartolome M, Balanzo X: Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J. 2000, 15: 757-763. 10.1034/j.1399-3003.2000.15d21.x.CrossRefPubMed
3.
go back to reference Ewig S, Torres A, Woodhead M: Assessment of pneumonia severity: a European perspective. Eur Respir J. 2006, 27: 6-8. 10.1183/09031936.06.00130205.CrossRefPubMed Ewig S, Torres A, Woodhead M: Assessment of pneumonia severity: a European perspective. Eur Respir J. 2006, 27: 6-8. 10.1183/09031936.06.00130205.CrossRefPubMed
4.
go back to reference Bauer TT, Ewig S, Marre R, Suttorp N, Welte T: CRB-65 predicts death from community-acquired pneumonia. J Intern Med. 2006, 260: 93-101. 10.1111/j.1365-2796.2006.01657.x.CrossRefPubMed Bauer TT, Ewig S, Marre R, Suttorp N, Welte T: CRB-65 predicts death from community-acquired pneumonia. J Intern Med. 2006, 260: 93-101. 10.1111/j.1365-2796.2006.01657.x.CrossRefPubMed
5.
go back to reference Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003, 374: 1-20. 10.1042/BJ20030407.CrossRefPubMedPubMedCentral Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003, 374: 1-20. 10.1042/BJ20030407.CrossRefPubMedPubMedCentral
6.
go back to reference Grutz G: New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. J Leukoc Biol. 2005, 77: 3-15.PubMed Grutz G: New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. J Leukoc Biol. 2005, 77: 3-15.PubMed
7.
go back to reference Schumann RR, Zweigner J: A novel acute-phase marker: lipopolysaccharide binding protein (LBP). Clin Chem Lab Med. 1999, 37: 271-274. 10.1515/CCLM.1999.047.CrossRefPubMed Schumann RR, Zweigner J: A novel acute-phase marker: lipopolysaccharide binding protein (LBP). Clin Chem Lab Med. 1999, 37: 271-274. 10.1515/CCLM.1999.047.CrossRefPubMed
8.
go back to reference Jones SA: Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol. 2005, 175: 3463-3468.CrossRefPubMed Jones SA: Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol. 2005, 175: 3463-3468.CrossRefPubMed
9.
go back to reference Fischer CP: Interleukin-6 in acute exercise and training: what is the biological relevance?. Exerc Immunol Rev. 2006, 12: 6-33.PubMed Fischer CP: Interleukin-6 in acute exercise and training: what is the biological relevance?. Exerc Immunol Rev. 2006, 12: 6-33.PubMed
10.
go back to reference Kruger S, Ewig S, Marre R, Papassotiriou J, Richter K, von Baum H, Suttorp N, Welte T: Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J. 2008, 31: 349-355. 10.1183/09031936.00054507.CrossRefPubMed Kruger S, Ewig S, Marre R, Papassotiriou J, Richter K, von Baum H, Suttorp N, Welte T: Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J. 2008, 31: 349-355. 10.1183/09031936.00054507.CrossRefPubMed
11.
go back to reference Kruger S, Ewig S, Papassotiriou J, Kunde J, Marre R, von Baum H, Suttor N, Welte T: Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res. 2009, 10: 65-10.1186/1465-9921-10-65.CrossRefPubMedPubMedCentral Kruger S, Ewig S, Papassotiriou J, Kunde J, Marre R, von Baum H, Suttor N, Welte T: Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res. 2009, 10: 65-10.1186/1465-9921-10-65.CrossRefPubMedPubMedCentral
12.
go back to reference Infektionen der tiefen Atemwege: Quality standards for microbiological diagnostic techniques for infectious diseases. Edited by: Mauch H, Lütticken R, Gatermann S. 2000, Munich: Urban & Fischer Verlag, 2011- Infektionen der tiefen Atemwege: Quality standards for microbiological diagnostic techniques for infectious diseases. Edited by: Mauch H, Lütticken R, Gatermann S. 2000, Munich: Urban & Fischer Verlag, 2011-
13.
go back to reference Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS: Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008, 27: 157-172. 10.1002/sim.2929.CrossRefPubMed Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS: Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008, 27: 157-172. 10.1002/sim.2929.CrossRefPubMed
14.
go back to reference Pencina MJ, D'Agostino RB, Steyerberg EW: Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011, 30: 11-21. 10.1002/sim.4085.CrossRefPubMed Pencina MJ, D'Agostino RB, Steyerberg EW: Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011, 30: 11-21. 10.1002/sim.4085.CrossRefPubMed
15.
go back to reference DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988, 44: 837-845. 10.2307/2531595.CrossRefPubMed DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988, 44: 837-845. 10.2307/2531595.CrossRefPubMed
16.
go back to reference Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997, 336: 243-250. 10.1056/NEJM199701233360402.CrossRefPubMed Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997, 336: 243-250. 10.1056/NEJM199701233360402.CrossRefPubMed
17.
go back to reference Capelastegui A, Espana PP, Quintana JM, Areitio I, Gorordo I, Egurrola M, Bilbao A: Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J. 2006, 27: 151-157. 10.1183/09031936.06.00062505.CrossRefPubMed Capelastegui A, Espana PP, Quintana JM, Areitio I, Gorordo I, Egurrola M, Bilbao A: Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J. 2006, 27: 151-157. 10.1183/09031936.06.00062505.CrossRefPubMed
18.
go back to reference Buising KL, Thursky KA, Black JF, MacGregor L, Street AC, Kennedy MP, Brown GV: A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax. 2006, 61: 419-424. 10.1136/thx.2005.051326.CrossRefPubMedPubMedCentral Buising KL, Thursky KA, Black JF, MacGregor L, Street AC, Kennedy MP, Brown GV: A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax. 2006, 61: 419-424. 10.1136/thx.2005.051326.CrossRefPubMedPubMedCentral
19.
go back to reference Kruger S, Ewig S, Kunde J, Hartmann O, Suttorp N, Welte T: Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in community-acquired pneumonia: results from the German Competence Network CAPNETZ. Thorax. 2010, 65: 208-214. 10.1136/thx.2009.121178.CrossRefPubMed Kruger S, Ewig S, Kunde J, Hartmann O, Suttorp N, Welte T: Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in community-acquired pneumonia: results from the German Competence Network CAPNETZ. Thorax. 2010, 65: 208-214. 10.1136/thx.2009.121178.CrossRefPubMed
20.
go back to reference Kruger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T: Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med. 2010, 182: 1426-1434. 10.1164/rccm.201003-0415OC.CrossRefPubMed Kruger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T: Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med. 2010, 182: 1426-1434. 10.1164/rccm.201003-0415OC.CrossRefPubMed
21.
go back to reference Dehoux MS, Boutten A, Ostinelli J, Seta N, Dombret MC, Crestani B, Deschenes M, Trouillet JL, Aubier M: Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med. 1994, 150: 710-716.CrossRefPubMed Dehoux MS, Boutten A, Ostinelli J, Seta N, Dombret MC, Crestani B, Deschenes M, Trouillet JL, Aubier M: Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med. 1994, 150: 710-716.CrossRefPubMed
22.
go back to reference Kolsuz M, Erginel S, Alatas O, Alatas F, Metintas M, Ucgun I, Harmanci E, Colak O: Acute phase reactants and cytokine levels in unilateral community-acquired pneumonia. Respiration. 2003, 70: 615-622. 10.1159/000075208.CrossRefPubMed Kolsuz M, Erginel S, Alatas O, Alatas F, Metintas M, Ucgun I, Harmanci E, Colak O: Acute phase reactants and cytokine levels in unilateral community-acquired pneumonia. Respiration. 2003, 70: 615-622. 10.1159/000075208.CrossRefPubMed
23.
go back to reference Wu CL, Chan MC, Chang GC, Lee YL, Chin CS, Chang KM, Hsu JY: Etiology and cytokine expression in patients requiring mechanical ventilation due to severe community-acquired pneumonia. J Formos Med Assoc. 2006, 105: 49-55. 10.1016/S0929-6646(09)60108-X.CrossRefPubMed Wu CL, Chan MC, Chang GC, Lee YL, Chin CS, Chang KM, Hsu JY: Etiology and cytokine expression in patients requiring mechanical ventilation due to severe community-acquired pneumonia. J Formos Med Assoc. 2006, 105: 49-55. 10.1016/S0929-6646(09)60108-X.CrossRefPubMed
24.
go back to reference Fernandez-Serrano S, Dorca J, Coromines M, Carratala J, Gudiol F, Manresa F: Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Diagn Lab Immunol. 2003, 10: 813-820.PubMedPubMedCentral Fernandez-Serrano S, Dorca J, Coromines M, Carratala J, Gudiol F, Manresa F: Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Diagn Lab Immunol. 2003, 10: 813-820.PubMedPubMedCentral
25.
go back to reference Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE, Parejo NA, Pribble JP, Lemke JH: Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis. 1999, 180: 1584-1589. 10.1086/315093.CrossRefPubMed Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE, Parejo NA, Pribble JP, Lemke JH: Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis. 1999, 180: 1584-1589. 10.1086/315093.CrossRefPubMed
26.
go back to reference Blairon L, Wittebole X, Laterre PF: Lipopolysaccharide-binding protein serum levels in patients with severe sepsis due to gram-positive and fungal infections. J Infect Dis. 2003, 187: 287-291. 10.1086/346046.CrossRefPubMed Blairon L, Wittebole X, Laterre PF: Lipopolysaccharide-binding protein serum levels in patients with severe sepsis due to gram-positive and fungal infections. J Infect Dis. 2003, 187: 287-291. 10.1086/346046.CrossRefPubMed
27.
go back to reference Masia M, Gutierrez F, Padilla S, Soldan B, Mirete C, Shum C, Hernandez I, Royo G, Martin-Hidalgo A: Clinical characterisation of pneumonia caused by atypical pathogens combining classic and novel predictors. Clin Microbiol Infect. 2007, 13: 153-161.CrossRefPubMed Masia M, Gutierrez F, Padilla S, Soldan B, Mirete C, Shum C, Hernandez I, Royo G, Martin-Hidalgo A: Clinical characterisation of pneumonia caused by atypical pathogens combining classic and novel predictors. Clin Microbiol Infect. 2007, 13: 153-161.CrossRefPubMed
28.
go back to reference Tejera A, Santolaria F, Diez ML, Aleman-Valls MR, Gonzalez-Reimers E, Martinez-Riera A, Milena-Abril A: Prognosis of community acquired pneumonia (CAP): value of triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflammatory response. Cytokine. 2007, 38: 117-123. 10.1016/j.cyto.2007.05.002.CrossRefPubMed Tejera A, Santolaria F, Diez ML, Aleman-Valls MR, Gonzalez-Reimers E, Martinez-Riera A, Milena-Abril A: Prognosis of community acquired pneumonia (CAP): value of triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflammatory response. Cytokine. 2007, 38: 117-123. 10.1016/j.cyto.2007.05.002.CrossRefPubMed
29.
go back to reference Ware JH: The limitations of risk factors as prognostic tools. N Engl J Med. 2006, 355: 2615-2617. 10.1056/NEJMp068249.CrossRefPubMed Ware JH: The limitations of risk factors as prognostic tools. N Engl J Med. 2006, 355: 2615-2617. 10.1056/NEJMp068249.CrossRefPubMed
30.
go back to reference Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, Fine J, Krichevsky A, Delude RL, Angus DC: Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med. 2007, 167: 1655-1663. 10.1001/archinte.167.15.1655.CrossRefPubMedPubMedCentral Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, Fine J, Krichevsky A, Delude RL, Angus DC: Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med. 2007, 167: 1655-1663. 10.1001/archinte.167.15.1655.CrossRefPubMedPubMedCentral
31.
go back to reference Taniguchi T, Koido Y, Aiboshi J, Yamashita T, Suzaki S, Kurokawa A: Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med. 1999, 27: 1262-1264. 10.1097/00003246-199907000-00005.CrossRefPubMed Taniguchi T, Koido Y, Aiboshi J, Yamashita T, Suzaki S, Kurokawa A: Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med. 1999, 27: 1262-1264. 10.1097/00003246-199907000-00005.CrossRefPubMed
32.
go back to reference Lekkou A, Karakantza M, Mouzaki A, Kalfarentzos F, Gogos CA: Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe infections. Clin Diagn Lab Immunol. 2004, 11: 161-167.PubMedPubMedCentral Lekkou A, Karakantza M, Mouzaki A, Kalfarentzos F, Gogos CA: Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe infections. Clin Diagn Lab Immunol. 2004, 11: 161-167.PubMedPubMedCentral
33.
go back to reference Ewig S, Torres A, Angeles MM, Angrill J, Rano A, de Roux A, Mensa J, Martinez JA, de la Bellacasa JP, Bauer T: Factors associated with unknown aetiology in patients with community-acquired pneumonia. Eur Respir J. 2002, 20: 1254-1262. 10.1183/09031936.02.01942001.CrossRefPubMed Ewig S, Torres A, Angeles MM, Angrill J, Rano A, de Roux A, Mensa J, Martinez JA, de la Bellacasa JP, Bauer T: Factors associated with unknown aetiology in patients with community-acquired pneumonia. Eur Respir J. 2002, 20: 1254-1262. 10.1183/09031936.02.01942001.CrossRefPubMed
34.
go back to reference Schultz MJ: Cytokines and host defense in pneumonia. Intensivmedizin und Notfallmedizin, Band 36, Heft 3. 1999, Darmstadt: Steinkopff-Verlag Schultz MJ: Cytokines and host defense in pneumonia. Intensivmedizin und Notfallmedizin, Band 36, Heft 3. 1999, Darmstadt: Steinkopff-Verlag
35.
go back to reference Menendez R, Cavalcanti M, Reyes S, Mensa J, Martinez R, Marcos MA, Filella X, Niederman M, Torres A: Markers of treatment failure in hospitalised community acquired pneumonia. Thorax. 2008, 63: 447-452. 10.1136/thx.2007.086785.CrossRefPubMed Menendez R, Cavalcanti M, Reyes S, Mensa J, Martinez R, Marcos MA, Filella X, Niederman M, Torres A: Markers of treatment failure in hospitalised community acquired pneumonia. Thorax. 2008, 63: 447-452. 10.1136/thx.2007.086785.CrossRefPubMed
36.
go back to reference Menendez R, Torres A: Treatment failure in community-acquired pneumonia. Chest. 2007, 132: 1348-1355. 10.1378/chest.06-1995.CrossRefPubMed Menendez R, Torres A: Treatment failure in community-acquired pneumonia. Chest. 2007, 132: 1348-1355. 10.1378/chest.06-1995.CrossRefPubMed
37.
go back to reference Masia M, Gutierrez F, Llorca B, Navarro JC, Mirete C, Padilla S, Hernandez I, Flores E: Serum concentrations of lipopolysaccharide-binding protein as a biochemical marker to differentiate microbial etiology in patients with community-acquired pneumonia. Clin Chem. 2004, 50: 1661-1664. 10.1373/clinchem.2004.031294.CrossRefPubMed Masia M, Gutierrez F, Llorca B, Navarro JC, Mirete C, Padilla S, Hernandez I, Flores E: Serum concentrations of lipopolysaccharide-binding protein as a biochemical marker to differentiate microbial etiology in patients with community-acquired pneumonia. Clin Chem. 2004, 50: 1661-1664. 10.1373/clinchem.2004.031294.CrossRefPubMed
Metadata
Title
Interleukin 6, lipopolysaccharide-binding protein and interleukin 10 in the prediction of risk and etiologic patterns in patients with community-acquired pneumonia: results from the German competence network CAPNETZ
Authors
Katrin Zobel
Peter Martus
Mathias W Pletz
Santiago Ewig
Michael Prediger
Tobias Welte
Frank Bühling
CAPNETZ study group
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2012
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/1471-2466-12-6

Other articles of this Issue 1/2012

BMC Pulmonary Medicine 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.